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Coelho et al. [1] investigated the use of C-reactive protein
(CRP) levels for monitoring of patients with severe
community-acquired pneumonia (CAP). They found that
patients without a decrease in CRP levels on treatment had
an increased mortality compared to patients with a rapid fall
of this marker. The authors did not discuss another important
use of the analysis of the time course of CRP levels in CAP
that applies to patients on both the intensive care unit (ICU)
and the general paediatric ward. Empyema fluid has been
identified as an important source of CRP in pneumonia [2].
Patients with empyema may have CRP levels of a similar
magnitude as the non-survivors in Coelho’s study on
admission [3]. Adults as well as children who develop
empyema were shown to have persistently elevated CRP or a
secondary rise of this parameter despite adequate antibiotic
treatment [3,4]. A persistently elevated or rising CRP level in
a patient on the ICU should, therefore, alert the clinician not
only to a potentially poor prognosis but also prompt a
reassessment of the patient with a chest X-ray and chest
ultrasound for the presence of an empyema that may require
surgical evacuation.
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We thank Dr Eisenhut for his wise commentary regarding our
published manuscript. It represents an important contribution
to this discussion.
In our study assessing severe CAP [1], patients whose CRP
levels remain elevated, those with non-response and biphasic
response patterns, had significantly higher mortality rates.
These persistently elevated CRP levels suggest an ongoing
inflammatory process that could be associated with a failure
of initial antibiotic therapy as well as with a septic
complication such as an empyema or an abscess, as Dr
Eisenhut pointed out. Likewise, in our clinical practice, we
also found elevated CRP levels in patients with empyema.
Similarly, in a paediatric patient population with pneumococal
CAP, Hsieh et al. [5] clearly demonstrated that continuously
elevated CRP levels were also associated with necrosis and
empyema. Although not specifically studied, we speculate
that CRP should present the same time course in patients
with ventilator-associated pneumonia complicated with
empyema.
As referenced by Dr Eisenhut, Chen et al. [2] found that, in
addition to serum CRP, pleural fluid CRP can also be useful in
the differentiation of complicated from uncomplicated pleural
effusions.
As a result, in patients with persistently elevated or rising
CRP levels an aggressive diagnostic and therapeutic
approach should be attempted in order to prevent further
clinical deterioration and to diagnose potential infectious
complications, not only an empyema, as Dr Eisenhut
mentioned, but also other complications, such as acalculous
cholecystitis, appendicitis or a catheter-related bloodstream
infection.Page 2 of 2
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